The interaction of adenovirus E1A with p300 family members modulates cellular gene expression to reduce tumorigenicity

Journal of Cellular Biochemistry

Volumn 100, Issue 4, 2007, Pages 929-940

  Miura, Tanya A ^a   Cook, James L ^b   Potter, Terence A ^c   Ryan, Sharon ^c   Routes, John M ^d,e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^e Midwest Athletes Against Childhood Cancer Inc   (United States)

Author keywords

Adenovirus; E1A; E7; Microarray; p300; Papillomavirus; Tumor immunity

Indexed keywords

E1A PROTEIN; PROTEIN E7; PROTEIN P300;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CYTOLYSIS; FIBROSARCOMA; GENE EXPRESSION REGULATION; METASTASIS INHIBITION; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SEROTYPE; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; UNINDEXED SEQUENCE; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION;

ADENOVIRUS E1A PROTEINS; ANIMALS; BLOTTING, NORTHERN; CELL LINE, TUMOR; E1A-ASSOCIATED P300 PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRIDAE; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 33847023082     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21057     Document Type: Article

References (53)

1. Berk AJ. 2005. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24:7673-7685.
2. Bernat A, Avvakumov N, Mymryk JS, Banks L. 2003. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22:5927-5937.
3. Bernhard EJ, Hagner B, Wong C, Lubenski I, Muschel RJ. 1995. The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer 60:718-724.
4. Boucheix C, Soria C, Mirshahi M, Soria J, Perrot JY, Fournier N, Billard M, Rosenfeld C. 1983. Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p24). Inhibition of aggregation by ALB6 Fab. FEBS Lett 161:289-295.
5. Brokaw JL, Yee CL, Münger K. 1994. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 205:603-607.
6. Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB. 2002. Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem 277:11392-11400.
7. Cajot JF, Sordat I, Silvestre T, Sordat B. 1997. Differential display cloning identifies motility-related protein (MRP1/ CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 57:2593-2597.
8. Chinnadurai G. 2004. Modulation of oncogenic transformation by the human adenovirus E1A C-terminal region. Curr Top Microbiol Immunol 273:139-161.
9. Cook JL, Krantz CK, Routes BA. 1996. Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc Natl Acad Sci USA 93:13985-13990.
10. Cook JL, Routes BA, Walker TA, Colvin KL, Routes JM. 1999. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury. Exp Cell Res 251:414-423.
11. Cook JL, Miura TA, Ikle DN, Lewis AM Jr, Routes JM. 2003. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res 63:3435-3443.
12. Egan C, Jelsma TN, Howe JA, Bayley ST, Ferguson B, Branton PE. 1988. Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol Cell Biol 8:3955-3959.
13. Frisch SM. 2004. E1A as a tumor suppressor gene: Commentary re S. Madhusudan et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 10:2905-2907.
14. Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg GI. 1990. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 5:75-83.
15. Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T, Nishino K, Goto H, Yoneda T, Kumagai T, Osaki T, Hayashi S, Aozasa K, Kawase I. 2003. Expression of tetraspanins in human lung cancer cells: Frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22:674-687.
16. Gorelik L, Flavell RA. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122.
17. Gross C, Hansch D, Gastpar R, Multhoff G. 2003a. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem 384:267-279.
18. Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. 2003b. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem 278:41173-41181.
19. Gulbins E. 2003. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 47:393-399.
20. Hung IH, Casareno RL, Labesse G, Mathews FS, Gitlin JD. 1998. HAH1 is a copper-binding protein with distinct amino acid residues mediating copper homeostasis and antioxidant defense. J Biol Chem 273:1749-1754.
21. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. 1993. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177:1231-1237.
22. 2+ and free iron pool by sulfur amino acid deprivation: The role of ferritin light chain down-regulation in prooxidant production. Biochem Pharmacol 63:647-657.
23. Kim DH, Chang JH, Lee KH, Lee H-Y, Kim S-J. 1997. Mechanism of E1A-induced transforming growth factor-beta (TGF-beta) resistance in mouse keratinocytes involves repression of TGF-beta type II receptor transcription. J Biol Chem 272:688-694.
24. Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DPJ, Harper P, Seckl M, Thomas H, Lemoine NR, Charnock M, Habib NA, Lechler R, Nicholls J, Pignatelli M, Ganesan TS. 2004. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 10:2986-2996.
25. Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE. 2003. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 98:1649-1657.
26. Missero C, Filvaroff E, Paolo Dotto G. 1991. Induction of transforming growth factor B1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc Natl Acad Sci USA 88:3489-3493.
27. Miura TA, Morris K, Ryan S, Cook JL, Routes JM. 2003. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-a-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J Immunol 170:4119-4126.
28. Miura TA, Li H, Morris K, Ryan S, Hembre K, Cook JL, Routes JM. 2004. Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages, but not NK cells. J Virol 78:4646-4654.
29. Miyake M, Nakano K, Ieki Y, Adachi M, Huang CL, Itoi S, Koh T, Taki T. 1995. Motility related protein 1 (MRP-1/ CD9) expression: Inverse correlation with metastases in breast cancer. Cancer Res 55:4127-4131.
30. Miyake M, Inufusa H, Adachi M, Ishida H, Hashida H, Tokuhara T, Kakehi Y. 2000. Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene 19:5221-5226.
31. Multhoff G. 2002. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia 18:576-585.
32. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. 2004. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460.
33. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. 2001. Papillomavirus type 16 ongogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-kB-responsive genes in cervical keratinocytes. J Virol 75:4283-4296.
34. Nishihara A, Hanai J-i, Imamura T, Miyazono K, Kawabata M. 1999. E1A inhibits transforming growth factor-beta signaling through binding to Smad proteins. J Biol Chem 274:28716-28723.
35. Panjwani NN, Popova L, Srivastava PK. 2002. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J Immunol 168:2997-3003.
36. Pozzatti R, McCormick M, Thompson MA, Khoury G. 1988. The E1a gene of adenovirus type 2 reduces the metastaticscription. potential of ras-transformed rat embryo cells. Molec Cell Biol 8:2984-2988.
37. Routes JM, Cook JL. 1995. E1A gene expression induces susceptibility to killing by NK cells following immortalization but not adenovirus infection of human cells. Virology 210:421-428.
38. Routes JM, Ryan S. 1995. Oncogenicity of human papillomavirus- or or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. J Virol 69:7639-7647.
39. Routes JM, Li H, Bayley ST, Ryan S, Klemm DJ. 1996. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance correlate with E1A-p300 binding. J Immunol 156:1055-1061.
40. Routes J, Ryan S, Clase A, Miura T, Kuhl A, Potter T, Cook J. 2000a. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J of Immunology 165:4522-4527.
41. Routes J, Ryan S, Li H, Steinke J, Cook J. 2000b. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology 277:48-57.
42. Routes JM, Morris K, Ellison MC, Ryan S. 2005a. Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms. J Virol 79:116-123.
43. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, Lanier LL. 2005b. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 202:1477-1482.
44. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R, Deissler H. 2003. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9:6426-6431.
45. Schadt EE, Li C, Ellis B, Wong WH. 2001. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 120-125.
46. Schiemann BJ, Neil JR, Schiemann WP. 2003. SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-b-signaling system. Mol Biol Cell 14:3977-3988.
47. Shallal S, Kornbluth J. 2000. CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood 96:224-233.
48. Srivastava P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395-425.
49. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel MA. 1988. Altered expression NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 E1a inhibition of experimental metastasis. Canc Res 48:6550-6554.
50. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. 1997. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol 27:1648-1656.
51. Wang H-GH, Rikitake Y, Carter MC, Yaciuk P, Abraham SE, Zerler B, Moran E. 1993. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol 67:476-488.
52. Watanabe M, Kitano T, Kondo T, Yabu T, Taguchi Y, Tashima M, Umehara H, Domae N, Uchiyama T, Okazaki T. 2004. Increase of nuclear ceramide through caspase-3-dependent regulation of the "sphingomyelin cycle" in Fas-induced apoptosis. Cancer Res 64:1000-1007.
53. Yamamoto M. 2004. Conditionally replicative adenovirus for gastrointestinal cancers. Expert Opinion Biol Therapy 4:1241-1250.